August 28, 2025 a 07:43 pm
INCY: Fundamental Ratio Analysis - Incyte Corporation
Incyte Corporation, a leader in biopharmaceutical innovation, focuses on creating therapeutics with global impact. With a diverse portfolio including JAKAFI, PEMAZYRE, and ICLUSIG, the company's pioneering efforts in various clinical stages highlight its potential in treating complex diseases. As industry dynamics evolve, Incyte's strategic collaborations and pipeline advancements could significantly influence its market position.
Fundamentals Rating
Incyte's fundamental rating presents strong potential, with generally favorable scores across key financial metrics.
| Category | Score | Visualization |
|---|---|---|
| Discounted Cash Flow | 4 | |
| Return On Equity | 5 | |
| Return On Assets | 5 | |
| Debt To Equity | 4 | |
| Price To Earnings | 2 | |
| Price To Book | 2 |
Historical Rating
The historical ratings indicate consistency in Incyte's performance metrics over time.
| Date | Overall Score | DCF | ROE | ROA | Debt To Equity | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-08-27 | 4 | 4 | 5 | 5 | 4 | 2 | 2 |
| Previous | 4 | 4 | 5 | 5 | 4 | 2 | 2 |
Analyst Price Targets
Analysts project a positive price trend for Incyte, with a consensus leaning towards a Buy rating.
| High | Low | Median | Consensus |
|---|---|---|---|
| $92 | $67 | $68 | $75.67 |
Analyst Sentiment
The sentiment among analysts is mostly favorable, with a strong Buy consensus.
| Recommendation | Count | Visualization |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 22 | |
| Hold | 19 | |
| Sell | 2 | |
| Strong Sell | 0 |
Conclusion
Incyte Corporation remains a promising player in the biotechnology sector, with strong fundamentals and a robust drug pipeline poised for future growth. Its collaborative efforts and strategic partnerships enhance its innovative potential. Despite the positive outlook and analyst recommendations, potential investors should consider market volatility and the regulatory environment. Overall, the stock presents a balanced risk-reward scenario, aligning with investor interests in the healthcare space.